Reference for MG132. Search for MG132

AI searches containing MG132

MG132

MG132

Chemical compound

MG132 is a potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). It belongs to the class of synthetic peptide aldehydes. It reduces

MG132

Amino acid

Organic compounds containing amine and carboxylic groups

and MG132, are artificially synthesized and retain their protecting groups, which have specific codes. Bortezomib is Pyz–Phe–boroLeu, and MG132 is Z–Leu–Leu–Leu–al

Amino acid

Amino_acid

Proteasome

Protein complexes which degrade ubiquitin-tagged proteins by proteolysis

of protease: an amino-terminal threonine protease. Bortezomib (Boronated MG132), a molecule developed by Millennium Pharmaceuticals and marketed as Velcade

Proteasome

Cycloheximide chase

degradation for a protein substrate of interest. Drug treatments (such as MG132) are also used to inhibit steps of degradation, followed by a cycloheximide

Cycloheximide chase

Cycloheximide_chase

Proteasome inhibitor

Drug

clinical trials. Epoxomicin is a naturally occurring selective inhibitor. MG132 is a synthesized peptide commonly used for in vitro studies. Beta-hydroxy

Proteasome inhibitor

Proteasome_inhibitor

RUNX2

Protein-coding gene in humans

cycle. Molecularly, It has been proposed that proteasome inhibition by MG132 can stabilize Runx2 protein levels in late G1 and S in MC3T3 cells, but

RUNX2

Unfolded protein response

Cellular stress response

ErSO activates the unfolded protein response and has anti cancer activity. MG132 is a proteosome inhibitor that blocks ERAD and therefore increases the accumulation

Unfolded protein response

Unfolded_protein_response

O-GlcNAc

Post-translational carbohydrate modification of proteins

resulted in decreased nuclear SREBP-1, but proteasomal inhibition with MG132 blocked this effect. OGT knockdown also increased the interaction between

O-GlcNAc

Alfred L. Goldberg

American cell biologist-biochemist (1942–2023)

(Myogenics/Proscript), which he founded, they introduced in 1994 the inhibitor, MG132, which has been used in many thousands of publications and has enabled major

Alfred L. Goldberg

Alfred_L._Goldberg

Stress granule

Cytoplasmic biomolecular condensates of proteins and RNA occurring in cells under stress

arsenite), endoplasmic reticulum stress (thapsigargin), proteasome inhibition (MG132), hyperosmotic stress, ultraviolet radiation, inhibition of eIF4A (pateamine

Stress granule

Stress_granule

Pyruvate dehydrogenase (lipoamide) beta

Protein-coding gene in the species Homo sapiens

demonstrated by PDH activity being restored in cells that were treated with MG132, which is known as proteasome inhibitor. The clinical manifestations of

Pyruvate dehydrogenase (lipoamide) beta

Pyruvate_dehydrogenase_(lipoamide)_beta

Mitotic exit

from degradation, such as in the presence of proteasome inhibitors like MG132, the mitotic exit induced by flavopiridol can be reversed. This finding

Mitotic exit

Mitotic_exit

List of prehistoric scheduled monuments in Powys (Montgomeryshire)

coflein NPRN: not yet identified. CPAT PRN not yet identified. Cadw SAM: MG132: Y Golfa Camp coflein NPRN: not yet identified. CPAT PRN not yet identified

List of prehistoric scheduled monuments in Powys (Montgomeryshire)

List_of_prehistoric_scheduled_monuments_in_Powys_(Montgomeryshire)

Manas Kumar Santra

"Engineering and In Vitro Evaluation of Acid Labile Cholesterol Tethered MG132 Nanoparticle for Targeting Ubiquitin-Proteasome System in Cancer". ChemistrySelect

Manas Kumar Santra

Manas_Kumar_Santra